INTRODUCTION
Natural antimicrobial peptides (AMPs), also known as genetically encoded antibiotic peptides, are an important component of innate immunity in most living organisms (Diamond et al., 2009; Kim et al., 2010; Zaiou, 2007) . Generally, their antimicrobial spectra are broad, acting against fungi, viruses, parasites, and both Gram-positive and Gram-negative bacteria, including, in some cases, multi-drug resistant bacteria (Ginsburg and Koren, 2008; Jenssen et al., 2006; Rivas et al., 2009; Ulvatne, 2003) . In addition, tumoricidal activities and insulinotropic activities have been also observed for certain AMPs (Abdel-Wahab et al., 2007; 2008; Gubern et al., 2006; Mader and Hoskin, 2006; Marenah et al., 2006; Kim et al., 2009; Papo and Shai, 2005) . In particular, some natural AMPs that have potent antimicrobial activity without toxicity against eukaryotic cells have emerged as potential therapeutic agents. After the discovery of the magainins in 1978 (Zasloff, 1987) , therapeutic and commercial development of novel anti-infective drugs has been attempted using natural AMPs and their analogues (Giuliani et al., 2007; Gordon et al., 2005; Oyston et al., 2009; Zasloff, 2002) . However, there remain several obstacles to their commercial and clinical applications, including high manufacturing costs and poor pharmaceutical and pharmacokinetic properties (Giuliani et al., 2007; Gordon et al., 2005; Zaiou, 2007; Zasloff, 2002) . Thus, despite many successful approaches to therapeutic applications, no AMP agent has yet received FDA approval (Giuliani et al., 2007; Gordon et al., 2005; Oyston et al., 2009; Zaiou, 2007; Zasloff, 2002) . At present, omiganan (MBI-226), a 12-residue, indolicidin-based peptide variant that we used in this study as a positive control for activity tests, is the most developed AMP (Gordon et al., 2005; Oyston et al., 2009; Rubinchik et al., 2009; Zasloff, 2002) , currently undergoing confirmatory Phase III clinical trials. To reduce production costs and facilitate pharmaceutical optimization, two important considerations for commercial development, AMPs with a shorter size and a simpler amino acid composition than omiganan would be more favorable lead molecules for studies. Then, for clinical development, bioactivity of any such peptide molecule can first be optimized in vitro. Towards this goal, we have used a natural AMP, brevinin-1EMa to develop short AMP variants with favorable bioactivity (Won et al., 2004) .
Brevinin-1EMa, formerly known as gaegurin 5, is a 24-residue AMP isolated from the skin of a species of Korean frog, Glandirana emeljanovi, formerly classified as Rana rugosa (Conlon, 2008; Park et al., 1994; Won et al., 2009) . The peptide belongs to the group of cationic, amphipathic α-helical AMPs, which represent a particularly abundant, widespread, and most well-characterized class of naturally occurring AMPs (Oren and Shai, 1998; Shai, 1999; Tossi et al., 2000; Zelezetsky and Tossi, 2006) . They are known to kill bacteria by selectively disintegrating bacterial membranes. Their positive charges are important to discriminate between the anionic surface of bacte-rial membranes and the zwitterionic membrane surface of eukaryotic cells, and their amphipathic helical structure is critical to promote membrane permeation by the peptides.
As part of an effort to develop new, low molecular mass peptide antibiotics, we have extensively investigated peptide sequence modifications to search for the shortest bioactive analogue of brevinin-1EMa (Won et al., 2004) . The N-terminal 11-residue fragment (sequence: FLGALFKVASK-NH 2 ) of brevinin1EMa is completely inactive, but we found that certain amino acid substitutions could confer activity to the peptide. We previously found that the most potent such peptide, GA-W2 (sequence: FLGWLFKWASK-NH 2 ), could be derived by substituting the amino acids at positions 4 and 8 with tryptophans. Despite the fact that GA-W2 is less than half the size of its parent molecule, it showed stronger bactericidal activity (Won et al., 2004) . Unfortunately, the hemolytic activity of GA-W2 at high concentrations was also severe. Thus, in this study, further amino acid substitutions were attempted to suppress hemolytic activity while maintaining or enhancing antimicrobial activity. We directed these modifications to also simplify the amino acid composition of the peptide, thereby making it more amenable to commercial production. This paper reports peptides improved from GA-W2, which may serve as activity-optimized candidates superior to omiganan for the development of new peptide antibiotics.
MATERIALS AND METHODS

Structural parameters and peptide preparation
As structural parameters, the mean residue hydrophobicity (<H>) and the mean residue hydrophobic moment (<µH>) were calculated from the amino acid sequences (Dathe et al., 2002; Nielsen et al., 2007) , on the Eisenberg scale for hydrophobicity (Eisenberg, 1984) , by using the HydroMCalc applet (http://www. bbcm.univ.trieste.it/~tossi/HydroCalc/HydroMCalc.html). After designing each peptide sequence, the chemically synthesized peptides, including the positive control omiganan (ILRWPWW-PWRRK-NH 2 ), were purchased as dry powders from the peptide manufacturer company AnyGen (Korea). All of the peptides were synthesized with C-terminal amidation to remove the Cterminal negative charge at neutral pH. The purity and the correct masses of the product peptides were determined by HPLC and mass spectrometry, respectively. For activity tests, a precise amount of each peptide powder was dissolved in PBS or in Luria-Bertani (LB) broth media to the designated concentration.
Antimicrobial assay
The antimicrobial activity of each peptide was determined against four Gram-positive bacterial strains (Bacillus subtilis ATCC 6633, Micrococcus luteus ATCC 10240, Staphylococcus aureus ATCC 6538p, and Staphylococcus epidermis ATCC 12228) and five Gram-negative strains (Escherichia coli ATCC 25922, Shigella dysentariae ATCC 9752, Salmonella typhomurium ATCC 14028, Klebsiella pneumoniae ATCC 10031, and Pseudomonas aeruginosa ATCC 27853). Antimicrobial susceptibility was assessed by the standard broth microdilution method to measure minimal inhibitory concentration (MIC) values. In brief, cell cultures (10 6 -10 8 cells/ml) in Luria-Bertani (LB) broth media were incubated in the presence of various concentrations (1.6-200 μg/ml, two-fold serial dilutions) of peptides, and the MIC was defined as the lowest peptide concentration that completely inhibits cell growth. The tests were performed with triplicate samples, and MIC values that were reproduced twice or three times in the three independent measurements were recorded. When there was no detectable activity at the highest concentration tested (200 μg/ml), 400 μg/ml was used for calculation of geometric mean of MIC values (GM), since the test was carried out by two-fold serial dilutions (Chen et al., 2005) .
Hemolytic assay and therapeutic index
In order to estimate hemolytic activities, suspensions of human red blood cells (10% v/v in PBS) were incubated for 30 min at 37°C in the presence of various concentrations of peptides (1.6-100 μg/ml, two-fold serial dilutions). After centrifugation, the absorbance of the supernatant at 550 nm was measured. The relative attenuation, as compared with that of the blood suspension treated with 0.2% Triton X-100, was defined as the percentage of hemolysis. The tests were performed with triplicate samples, and the average values of the three independent measurements were recorded. The minimal hemolytic concentration (MHC) value was determined as the lowest peptide concentration that produces 5% or more hemolysis (Chen et al., 2002; Dathe et al., 2002; Zhu et al., 2007) . When there was no significant hemolysis at the highest concentration tested (100 μg/ml), 200 μg/ml was used for calculation of the pseudotherapeutic index (TI′), since the test was carried out by twofold serial dilutions (Chen et al., 2005) . TI′ was defined as the ratio of the MHC value to the GM (geometric mean of MICs) value (TI′ = MHC/GM).
RESULTS AND DISCUSSION
Amino acid sequences of the peptide analogues generated in this study are summarized in Fig. 1 . To design each peptide sequence, we used the helical wheel diagrams shown in Fig. 2 . The starting molecule, GA-W2 (peptide no. 0.0), has been previously revealed to adopt an amphipathic α-helical structure by converging the hydrophobic residues to one side and the hydrophilic residues to the other side of the helical axis (Won et al., 2004; . The two tryptophan residues were located at the critical amphipathic interface between the end of the hydrophilic side and the start of the hydrophobic side, as seen in the helical wheel projection (Fig. 2) . This specific location of tryptophan is critical for peptide activity, as it stabilizes the helical structure and anchors it into the bacterial membrane (Won et al., 2002; 2004; . Thus, in all of the present variants, the two tryptophans (W4 and W8) were conserved. Also, two hydrophobic phenylalanines (F1 and F6) and two positive-charged lysines (K7 and K11) were fixed to maintain the fundamentally amphi- pathic structure and positive charges, which are known to be important for activity (Won et al., 2002; 2004; . In contrast, the non-positive, hydrophilic S10 and the neutral G3 were targeted for initial substitutions.
The first set of changes tested additional tryptophanyl substitutions. S10 alone or both the G3 and S10 residues were substituted by tryptophans, thereby generating the GA-W3 (peptide no. 1.0) and GA-W4 (peptide no. 1.1) variants, respectively.
Judging from GM value of GA-W3 (Table 1) , the S10W substitution of GA-W2 increased antimicrobial activity more than 2-fold. In contrast, the hemolytic activity of GA-W3 was significantly lower than that of GA-W2 (Fig. 3) , although it was still severe at high concentrations (MHC value of 50 µg/ml; Table 2 ). The antimicrobial activity enhancing effect by the S10W substitution was more remarkable against Gram-positive than Gramnegative bacteria and was further increased by the G3W/S10W double substitution (Table 1 ; GA-W4, peptide no. 1.2). However, the double tryptophanyl substitution almost abolished antibacterial activity against Gram-negative bacteria (Table 1) , and hardly decreased hemolytic activity (Fig. 3) . Other substitutions were directed to increase positive charges by introducing more lysines. The GA-K3 (peptide no. 2.0) and GA-K4 (peptide no. 2.1) were generated by a S10K and a G3K/S10K double substitution, respectively (Fig. 2) . The S10K substitution increased antibacterial activity (approximately 3.7-fold, based on GM values of GA-W2 and GA-K3 in Table 1 ) and significantly decreased hemolytic activity (compare between GA-W2 and GA-K3 in Fig. 3 ), although it was still severe at high concentrations (MHC value of 50 µg/ml; Table 2 ). Then, the antimicrobial activity of GA-K4 with the G3K/S10K double substitution was somewhat stronger than that of GA-K3, with just the S10K substitution (Table 1) . However, hemolytic activity was significantly increased in the GA-K4 variant (Fig. 3) . It seemed that the tightly organized amphipathicity by the G3K/ S10K double substitution stabilizes membrane interactions at both bacterial cells and human erythrocytes. This explanation is consistent with the result that GA-W4 was also more hemolytic than GA-W3 (Fig. 3) .
Because it exhibited the most potent antimicrobial activity, despite strong hemolytic activity, the GA-K4 peptide was employed as a template for further tests of amino acid substitutions, to alleviate its severe hemolytic activity. Five structural parameters, including conformation (χ), charge (Q), hydrophobicity (H), hydrophobic moment (μH) or amphipathicity (A), and polar angle (θ) are generally known as structural determinants of antimicrobial peptide activity (Chou et al., 2008; Dathe et al., 2002; Nielsen et al., 2007; Yeaman and Yount, 2003) . In particular, it has been suggested that high hydrophobicity and hydrophobic moment are correlated with increased hemolytic activity, whilst antimicrobial activity is less dependent on these factors (Chou et al., 2008; Yeaman and Yount, 2003) . Therefore, we anticipated that the hemolytic activity of GA-K4 could be suppressed by modulating the mean residue hydrophobicity (<H>) and hydrophobic moment (<μH>) values (Table 2) . To test this possibility, three analogues of GA-K4 were generated by leucine to alanine or alanine to leucine substitutions. As expected from the increased values of <H> and <μH> (Table 2) , the A9L substitution of GA-K4 resulted in significant increase of hemolytic activity ( Fig. 3 ; GA-K4L, peptide no. 2.11) and moderate decrease of antimicrobial activity (Table 1 ). In particular, the GA-K4L peptide that has the largest <μH> value among all of the present peptides showed the strongest hemolytic activity at high concentrations (Fig. 3) , evidencing the fact that hydrophobic moment is one of the critical factors for hemolytic activity. In contrast, reduced hemolytic activity could be observed from the GA-K4A (peptide no. 2.12), where both leucines of GA-K4 were substituted with less hydrophobic alanines, thereby lowering both the <H> and <μH> values (Table 2) . Particularly, the GA-K4A peptide that has the lowest <H> value among all of the present peptides showed negligible hemolytic activity even at high concentrations, in support of the fact that hydrophobicity is also one of the critical factors for hemolytic activity. Unfortunately, however, antimicrobial activity was also significantly impaired in the GA-K4AL peptide (Table 1) . Thus, we generated GA-K4AL (peptide no. 2.13), in expectation of reduced hemolytic activity without decrease of antimicrobial activity. By substituting the two leucines of GA-K4 with alanines and the alanine with a leucine (Figs. 1 and 2) , the <H> and <µH> values of GA-K4AL was adjusted to be lower than those of GA-K4 but higher than those of GA-K4A. Finally, the most favorable activity could be obtained from the GA-K4AL peptide. Its hemolytic activity was almost negligible as observed for GA-K4A (Fig.  3) , while the potent antimicrobial activity was maintained or a little bit more improved; i.e. the GM value of GA-K4AL is slightly lower than that of GA-K4 (Table 1) .
Activities of the present peptide analogues were compared with that of the known peptide agent, omiganan. Since our peptides are one residue shorter than omiganan, comparable activities can indicate that may be superior to omiganan. As shown in Table 1 , some peptides, including GA-W3, GA-K3, GA-K4, GA-K4L, and GA-K4AL, were observed to even be more potent than omiganan. To evaluate the peptides for their potential as therapeutic candidates, their pseudo-therapeutic index (TI′) values were estimated and compared with the value of omiganan (Table 2) . Although it is distinct from the typical therapeutic index (TI = LD 50 /ED 50 ), the TI′ value is useful for relative comparison of selectivity or safety between peptides, since it represents the balance between antimicrobial and hemolytic activities (Chen et al., 2005; Chou et al., 2008; Zhu et al., 2007) . As shown in Table 2 , the TI′ value was more than 43-folds improved from 0.5 for the initial template, GA-W2, to 21.7 for the final analogue, GA-K4AL. It corresponds to 32-and 53-fold increase against Gram-positive and Gram-negative bacteria, respectively. Finally, GA-K4AL could possess more than 5-fold higher TI′ even than omiganan.
The mode of action of the present peptides remains to be investigated in detail. However, it has generally been accepted that the membrane permeation of amphipathic α-helical AMPs is mainly accomplished via either a 'pore-forming' mechanism or a 'carpet-like' mechanism (Chia et al., 2002; Shai and Oren, 2001; Tossi et al., 2000; Zelezetsky and Tossi, 2006) . In particular, when acting via the pore-forming mechanism, in which the peptide oligomers form helical bundles upon membrane binding, the peptides tend to be selectively active against Gram-positive bacteria, because they do not readily cross the outer membrane of Gram-negative bacteria (Chia et al., 2002; Shai and Oren, 2001 ). In contrast, peptides acting via the carpet-like mechanism are expected to possess activity against both Gram-positive and Gram-negative bacteria. Thus, the GA-W4 peptide in this study, which showed a marked Grampositive selectivity, may act via the pore-forming mechanism, while the others with rather higher activity against Grampositive than against Gram-negative strains act via the carpetlike or via both mechanisms.
In summary, this study aimed to generate useful candidates for developing novel peptide antibiotics. Thus, using an antimicrobial and hemolytic peptide, GA-W2, as a template, we used a rational approach to sequence modification to optimize peptide activity. The properties of the GA-W2 peptide could be improved, thereby generating better candidates with increased antimicrobial activity and/or decreased hemolytic activity. Among the GA-W2 variants, the GA-K4AL peptide appears to be the best candidate, as it was the most potent molecule with no significant hemolytic activity. Compared to omiganan, which has already reached clinical trials, the GA-K4A has better properties: shorter length (11 residues versus 12 in omiganan), simpler composition (four kinds of amino acids versus six in omiganan), stronger antimicrobial activity (Table 1) , and weaker hemolytic activity (Table 2 and Fig. 3 ).
Taken together, we expect that our undecapeptides can serve as useful lead molecules for novel antibiotic development, and some of them, including GA-K4AL, are currently undergoing preclinical tests to explore the potential for further clinical and commercial development.
